Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain (PARAJUG)
This study is currently recruiting participants.
Verified January 2013 by University Hospital, Clermont-Ferrand
Sponsor:
University Hospital, Clermont-Ferrand
Collaborators:
Dr Gisèle PICKERING, Clinical Pharmacology Center, Inserm 501, Clermont-Ferrand Hospital
Pr Jeannot SCHIMDT, Emergency Department, Clermont-Ferrand Hospital
Dr Farès MOUSTAFA, Emergency Department, Clermont-Ferrand Hospital
Pr Claude Dubray, Clinical Pharmacology Center, Inserm 501, Clermont-Ferrand Hospital
Bruno PEREIRA, Clinical Research Direction and innovation, Clermont-Ferrand Hospital
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT01586143
First received: April 10, 2012
Last updated: January 11, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Pain |
Drug: paracetamol Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
| Official Title: | Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain |
Resource links provided by NLM:
Further study details as provided by University Hospital, Clermont-Ferrand:
Primary Outcome Measures:
- Pain score measured by visual analogue scale [ Time Frame: at T0 + 120 minutes ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 44 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: transbuccal paracetamol 125 mg
This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
|
Drug: paracetamol
This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
|
|
Placebo Comparator: placebo
This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
|
Drug: Placebo |
Detailed Description:
This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient admitted to emergency departments with trauma of upper or lower limbs (sprains, muscle contusions,…) associated with intensity moderate of acute pain (VAS between 4 and 6) which require infusion IV of paracetamol 1g.
- Patient takes any chronic treatment which considered incompatible with study.
- Patient between 18 and 60.
- Male or female.
- Sufficient cooperation and understanding to comply to the requirements of study.
- Acceptance to give a written consent.
- Affiliation at system of French social security.
- Inscription or acceptation of inscription at national register of voluntaries participant at research
Exclusion Criteria:
- Against paracetamol-indication: hypersensitivity known at paracétamol, antecedent hepatitis B or C, severe renal insufficiency and liver failure.
- Patient with medical or surgical antecedents.
- Patient with progressive disease at balance of inclusion.
- Alcoholism suspicion or toxicomany at intake.
- Patient who presents any inflammation or ulcerative pathology about buccal mucosa.
- Patient who refuses to ingest alcohol for personal reasons.
- Woman in childbearing age not using effective contraceptive method, pregnant or lactating woman.
- Patient who participated in another clinical trial, located in exclusion period or received benefits > 4500 euros during 12 months before the beginning of trial.
- Patient with cooperation and understanding insufficiency to comply to the requirements of protocol
- Patient with social protection
- No affiliation at system of French social security
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01586143
Contacts
| Contact: Patrick LACARIN | 04 73 75 11 95 | placarin@chu-clermontferrand.fr |
Locations
| France | |
| CHU Clermont-Ferrand | Recruiting |
| Clermont-Ferrand, France, 63003 | |
| Contact: Patrick LACARIN 04 73 75 11 95 placarin@chu-clermontferrand.fr | |
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Dr Gisèle PICKERING, Clinical Pharmacology Center, Inserm 501, Clermont-Ferrand Hospital
Pr Jeannot SCHIMDT, Emergency Department, Clermont-Ferrand Hospital
Dr Farès MOUSTAFA, Emergency Department, Clermont-Ferrand Hospital
Pr Claude Dubray, Clinical Pharmacology Center, Inserm 501, Clermont-Ferrand Hospital
Bruno PEREIRA, Clinical Research Direction and innovation, Clermont-Ferrand Hospital
Investigators
| Principal Investigator: | Gisele PICKERING | University Hospital, Clermont-Ferrand |
More Information
No publications provided
| Responsible Party: | University Hospital, Clermont-Ferrand |
| ClinicalTrials.gov Identifier: | NCT01586143 History of Changes |
| Other Study ID Numbers: | CHU-0118 |
| Study First Received: | April 10, 2012 |
| Last Updated: | January 11, 2013 |
| Health Authority: | France: Ministry of Health |
Keywords provided by University Hospital, Clermont-Ferrand:
|
Paracetamol by permucosal route, Paracetamol by intraveinous route, Pain. Patient with minor trauma of lower limb and/or superior limb (sprains, muscle contusions, …). |
Additional relevant MeSH terms:
|
Acetaminophen Antipyretics Physiological Effects of Drugs Pharmacologic Actions Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013